Assessment of results of using three types of vascular access for isolated hepatic chemoperfusion

Abstract

INTRODUCTION: Uveal melanoma (UM) is an oncological disease, which develops metastases mainly to the liver. One of treatments for this pathology is isolated hepatic chemoperfusion (IHCP). The implementation of this method requires surgical isolation of the liver from the systemic circulation and the use of a heart-lung machine. Due to a small number of observations of this treatment method in the world, the optimal vascular access for its implementation has not been determined so far.

AIM: To analyze the in-hospital results of IHCP in patients with UM metastases performed from three different vascular accesses.

MATERIALS AND METHODS: Over three years, 38 IHCP procedures were performed of the Kostroma Clinical Oncological Dispensary. Depending on the vessels into which the cannula for perfusion with Melphalan was inserted, patients were divided into 3 groups: group 1 with cava-porto-arterial access (perfusion into the inferior vena cava, portal vein, and common hepatic artery), n = 14; group 2 with cava-arterial access (perfusion into the inferior vena cava and common hepatic artery), n = 21; group 3 with a forced access, n = 3. The study took into account major complications: death, bleeding; and minor complications: tumor lysis syndrome, abscess of the left lobe of the liver, peritonitis, a systole, deep vein thrombosis of the lower limbs, hydrothorax, acute liver failure, anasarca, polyserositis, ischemic cholangiopathy, thrombosis of the common hepatic artery, detachment of the common hepatic artery intima. A combined endpoint was the achievement of at least one of the listed complications. In case of several complications in one patient, they were not summed up and were considered as ‘1’.

RESULTS: In the postoperative period, the highest number of bleedings including those requiring revision, was noted in groups 1 and 3. The combined endpoint in the total sample made 42.11% and was lowest in group 2. Fatal outcomes were recorded in 3 cases (2 in group 1 and 1 in group 2), and were caused by increasing liver failure.

CONCLUSION: The lowest number of complications IHCP was identified with cava-arterial access. Further continuation of the study is necessary to investigate the immediate and remote outcomes of IHCP.

Keywords

uveal melanoma / uveal melanoma metastases / isolated hepatic chemoperfusion

References

[1] Amaro A, Gangemi R, Piaggio F, et al. The biology of uveal melanoma. Cancer Metastasis Rev. 2017;36(1):109–40. doi: 10.1007/s10555-017-9663-3

[2] Amaro A., Gangemi R., Piaggio F., et al. The biology of uveal melanoma // Cancer Metastasis Rev. 2017. Vol. 36, No. 1. P. 109–140. doi: 10.1007/s10555-017-9663-3

[3] Aronow ME, Topham AK, Singh AD. Uveal Melanoma: 5-Year Update on Incidence, Treatment, and Survival (SEER 1973–2013). Ocul Oncol Pathol. 2018;4(3):145–51. doi: 10.1159/000480640

[4] Aronow M.E., Topham A.K., Singh A.D. Uveal Melanoma: 5-Year Update on Incidence, Treatment, and Survival (SEER 1973–2013) // Ocul. Oncol. Pathol. 2018. Vol. 4, No. 3. P. 145–151. doi: 10.1159/000480640

[5] Korotkikh AV, Babunashvili AM, Kazantsev AN, et al. Distal Radial Artery Access in Noncoronary Procedures. Curr Probl Cardiol. 2023; 48(8):101207. doi: 10.1016/j.cpcardiol.2022.101207

[6] Korotkikh A.V., Babunashvili A.M., Kazantsev A.N., et al. Distal Radial Artery Access in Noncoronary Procedures // Curr. Probl. Cardiol. 2023. Vol. 48, No. 8. P. 101207. doi: 10.1016/j.cpcardiol.2022.101207

[7] Kaliki S, Shields CL. Uveal melanoma: relatively rare but deadly cancer. Eye (Lond). 2017;31(2):241–57. doi: 10.1038/eye.2016.275

[8] Kaliki S., Shields C.L. Uveal melanoma: relatively rare but deadly cancer // Eye (Lond.). 2017. Vol. 31, No. 2. P. 241–257. doi: 10.1038/eye.2016.275

[9] Unguryan VM, Kazantsev AN, Korotkikh AV, et al. Isolated liver chemo perfusion for hepatic metastases from uveal melanoma: a report of 38 cases. Indian J Thorac Cardiovasc Surg. 2024;40(2):198–204. doi: 10.1007/s12055-023-01620-6

[10] Unguryan V.M., Kazantsev A.N., Korotkikh A.V., et al. Isolated liver chemo perfusion for hepatic metastases from uveal melanoma: a report of 38 cases // Indian J. Thorac. Cardiovasc. Surg. 2024. Vol. 40, No. 2. P. 198–204. doi: 10.1007/s12055-023-01620-6

[11] Shields CL, Shields JA. Ocular melanoma: relatively rare but requiring respect. Clin Dermatol. 2009;27(1):122–33. doi: 10.1016/j.clin dermatol.2008.09.010

[12] Shields C.L., Shields J.A. Ocular melanoma: relatively rare but requiring respect // Clin. Dermatol. 2009. Vol. 27, No. 1. P. 122–133. doi: 10.1016/j.clindermatol.2008.09.010

[13] Ulmer A, Beutel J, Süsskind D, et al. Visualization of circulating melanoma cells in peripheral blood of patients with primary uveal melanoma. Clin Cancer Res. 2008;14(14):4469–74. doi: 10.1158/1078-0432.ccr-08-0012

[14] Ulmer A., Beutel J., Süsskind D., et al. Visualization of circulating melanoma cells in peripheral blood of patients with primary uveal melanoma // Clin. Cancer Res. 2008. Vol. 14, No. 14. P. 4469–4474. doi: 10.1158/1078-0432.ccr-08-0012

[15] Korotkikh AV, Babunashvili AM, Kazantsev AN, et al. Distal Radial Access: Is There a Clinical Benefit? Cardiol Rev. 2024;32(2):110–3. doi: 10.1097/crd.0000000000000472

[16] Korotkikh A.V., Babunashvili A.M., Kazantsev A.N., et al. Distal Radial Access: Is There a Clinical Benefit? // Cardiol. Rev. 2024. Vol. 32, No. 2. P. 110–113. doi: 10.1097/crd.0000000000000472

[17] Rowcroft A, Loveday BPT, Thomson BNJ, et al. Systematic review of liver directed therapy for uveal melanoma hepatic metastases. HPB (Oxford). 2020;22(4):497–505. doi: 10.1016/j.hpb.2019.11.002

[18] Rowcroft A., Loveday B.P.T., Thomson B.N.J., et al. Systematic review of liver directed therapy for uveal melanoma hepatic metastases // HPB (Oxford). 2020. Vol. 22, No. 4. P. 497–505. doi: 10.1016/j.hpb.2019.11.002

[19] Ben–Shabat I, Belgrano V, Ny L, et al. Long-Term Follow-Up Evaluation of 68 Patients with Uveal Melanoma Liver Metastases Treated with Isolated Hepatic Perfusion. Ann Surg Oncol. 2016;23(4):1327–34. doi: 10.1245/s10434-015-4982-5

[20] Ben–Shabat I., Belgrano V., Ny L., et al. Long-Term Follow-Up Evaluation of 68 Patients with Uveal Melanoma Liver Metastases Treated with Isolated Hepatic Perfusion // Ann. Surg. Oncol. 2016. Vol. 23, No. 4. P. 1327–1334. doi: 10.1245/s10434-015-4982-5

[21] Kaprin AD, Ivanov SA, Petrov LO, et al. Isolated endovascular liver chemoperfusion for liver metastases of uveal melanoma. Pirogov Russian Journal of Surgery. 2023;(8):75–80. (In Russ). doi: 10.17116/hirurgia202308175

[22] Каприн А.Д., Иванов С.А., Петров Л.О., и др. Способ изолированной эндоваскулярной химиоперфузии печени при метастазах увеальной меланомы в печень // Хирургия. Журнал им. Н.И. Пирогова. 2023. № 8. С. 75–80. doi: 10.17116/hirurgia202308175

[23] Ben–Shabat I, Belgrano V, Hansson C. et al. The effect of perfusate buffering on toxicity and response in isolated hepatic perfusion for uveal melanoma liver metastases. Int J Hyperthermia. 2017;33(4): 483–8. doi: 10.1080/02656736.2017.1286046

[24] Ben–Shabat I., Belgrano V., Hansson C., et al. The effect of perfusate buffering on toxicity and response in isolated hepatic perfusion for uveal melanoma liver metastases // Int. J. Hyperthermia. 2017. Vol. 33, No. 4. P. 483–488. doi: 10.1080/02656736.2017.1286046

[25] Korotkikh AV, Babunashvili AM, Kazantsev AN, et al. A narrative review of history, advantages, future developments of the distal radial access. J Vasc Access. 2024;25(3):745–52. doi: 10.1177/11297298221129416

[26] Korotkikh A.V., Babunashvili A.M., Kazantsev A.N., et al. A narrative review of history, advantages, future developments of the distal radial access // J. Vasc. Access. 2024. Vol. 25, No. 3. P. 745–752. doi: 10.1177/11297298221129416

RIGHTS & PERMISSIONS

Eco-Vector